Decanter C
Service d'AMP de l'hôpital Jeanne-de-Flandre, CHRU de Lille, 6, rue Eugène-Avinée, 59037 Lille cedex, France.
Gynecol Obstet Fertil. 2013 Sep;41(9):515-7. doi: 10.1016/j.gyobfe.2013.07.018. Epub 2013 Aug 27.
The number of young cancer women theoretically eligible for fertility preservation before chemotherapy is steadily increasing. Nevertheless, the number of patients who can really benefit from complex ART techniques such as ovarian tissue or oocyte/embryo cryopreservation remains very low mainly because of a too short time-interval between the cancer diagnosis and its treatment. Lack of adequate information regarding post treatment infertility risk and logistical difficulties to access to a highly specialized cryopreservation centre are also reasons of importance. It is now well-established that these patients are at high risk of infertility even if they return to a normal ovarian function. Therefore, for patients who could not benefit from fertility preservation before cancer treatment, and who have recovered spontaneous menstrual cycle, one might raise the question of oocyte freezing once the cancer cured.
理论上，化疗前符合生育力保存条件的年轻癌症女性数量正在稳步增加。然而，真正能够从诸如卵巢组织或卵母细胞/胚胎冷冻保存等复杂辅助生殖技术中获益的患者数量仍然非常少，主要原因是癌症诊断与治疗之间的时间间隔过短。缺乏关于治疗后不孕风险的充分信息以及前往高度专业化冷冻保存中心的后勤困难也是重要原因。现在已经明确，即使这些患者恢复了正常卵巢功能，她们仍面临高不孕风险。因此，对于那些在癌症治疗前未能从生育力保存中获益且已恢复自然月经周期的患者，在癌症治愈后可能会引发卵母细胞冷冻的问题。
